Dr. Joseph Mikhael Wraps Up ASCO 2020
IMF Chief Medical Officer Dr. Joseph Mikhael (TGen at the City of Hope — Phoenix) discusses the top multiple myeloma abstracts from the 2020 American Society of Clinical Oncology meeting.
Topics include:
- the ENDURANCE Trial (a plenary abstract) that compared the use of Kyprolis (carfilzomib), Revlimid (lenalidomide) and dexamethasone (KRd) to the use of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone (VRd) in non-high-risk patients who were not planning to immediately undergo stem transplant
- CAR T-cell abstracts, including discussion of three oral abstracts: KarMMa trial, the CARTITUDE-1 trial, and the EVOLVE study
- A clinical science abstract on the bispecific antibody teclistamab
- The oral abstract on the DREAMM-6 study, which looks at the safety and tolerability of belantamab mafodotin in combination with Velcade (bortezomib) and dexamethasone in relapsed refractory multiple myeloma
- A long-term follow-up of the StaMINA Trial (one oral abstract), which was originally designed to answer the question, "If someone gets induction therapy and a singe transplant, do they need more?" This study randomizes three different maintenance scenarios post-transplant.
JOSEPH MIKHAEL, MD
Dr. Joseph Mikhael is a world-renowned multiple myeloma expert. In his position with the IMF, he works closely with the Board Chairman, Dr. Brian G.M. Durie, to advance the mission of the organization in research, education, advocacy, and patient care to improve the lives of patients with myeloma. Dr. Mikhael has conducted dozens of clinical trials in the field of multiple myeloma and has contributed to the development of many novel drugs. He has served as a Professor of Medicine at the Mayo Clinic, an Associate Dean at the Mayo Clinic School of Graduate Medical Education, and as the Deputy Director of Education at the Mayo Clinic Cancer Center. Dr. Mikhael also serves as a councilor on the American Society of Hematology (ASH) Executive Committee and is involved in mentoring the next generation of hematologists. He did his medical training in Canada, having completed medical school at the University of Ottawa, his hematology training at the University of Toronto, and a Multiple Myeloma Fellowship at Princess Margaret Hospital. He also has a master’s degree in education from the University of Toronto. Dr. Mikhael remains in clinical and academic medicine with the City of Hope Cancer Center in California. Visit Dr. Joseph Mikhael’s full biography
